Gene: TP53 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1064793881
rs1064793881
TP53
T 0.700 GeneticVariation CLINVAR

dbSNP: rs121912664
rs121912664
TP53
T 0.700 CausalMutation CLINVAR

dbSNP: rs1567549584
rs1567549584
TP53
C 0.700 GeneticVariation CLINVAR

dbSNP: rs397514495
rs397514495
TP53
T 0.700 GeneticVariation CLINVAR

dbSNP: rs587782144
rs587782144
TP53
G 0.700 GeneticVariation CLINVAR

dbSNP: rs1057519991
rs1057519991
TP53
0.710 GeneticVariation BEFREE Combinations of the Y113H and H139R polymorphic EPHX1 variants have been assumed to alter the enzyme activity and thus the risk of squamous cell head and neck cancer (SCCHN). 12491039

2003
dbSNP: rs876659477
rs876659477
TP53
0.010 GeneticVariation BEFREE Combinations of the Y113H and H139R polymorphic EPHX1 variants have been assumed to alter the enzyme activity and thus the risk of squamous cell head and neck cancer (SCCHN). 12491039

2003
dbSNP: rs1042522
rs1042522
TP53
0.050 GeneticVariation BEFREE We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs. 17118968

2007
dbSNP: rs1131691014
rs1131691014
TP53
0.030 GeneticVariation BEFREE We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs. 17118968

2007
dbSNP: rs878854066
rs878854066
TP53
0.030 GeneticVariation BEFREE We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs. 17118968

2007
dbSNP: rs1057519975
rs1057519975
TP53
0.010 GeneticVariation BEFREE We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN</span>, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs. 17118968

2007
dbSNP: rs1131691036
rs1131691036
TP53
0.010 GeneticVariation BEFREE We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN</span>, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs. 17118968

2007
dbSNP: rs121912666
rs121912666
TP53
0.710 GeneticVariation BEFREE Our analysis of p53 in 10 additional HLA-A2(+) SCCHN tumors detected the p53 Y220C in 2/10 tumors raising the overall frequency of the p53 Y220C mutation to 6/50 (12%) HLA-A2(+) SCCHN tumors. 17294448

2007
dbSNP: rs1042522
rs1042522
TP53
0.050 GeneticVariation BEFREE Stratification analyses showed that a reduced risk associated with the -606CC genotype was more pronounced in subgroups of non-smokers, non-drinkers, younger subjects (defined as ≤57 years), carriers of the TP53 Arg/Arg (rs1042522) genotype, patients with oropharyngeal cancer or late-stage SCCHN. 20935061

2010
dbSNP: rs1042522
rs1042522
TP53
0.050 GeneticVariation BEFREE Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70. 24289637

2013
dbSNP: rs1131691014
rs1131691014
TP53
0.030 GeneticVariation BEFREE Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70. 24289637

2013
dbSNP: rs878854066
rs878854066
TP53
0.030 GeneticVariation BEFREE Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70. 24289637

2013
dbSNP: rs1042522
rs1042522
TP53
0.050 GeneticVariation BEFREE The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk. 24370206

2014
dbSNP: rs1131691014
rs1131691014
TP53
0.030 GeneticVariation BEFREE The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk. 24370206

2014
dbSNP: rs878854066
rs878854066
TP53
0.030 GeneticVariation BEFREE The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk. 24370206

2014
dbSNP: rs1042522
rs1042522
TP53
0.050 GeneticVariation BEFREE This study identified that individuals carrying the arginine allele at rs1042522 have an increased odds ratio of HNSCC. 26099726

2015
dbSNP: rs1057519991
rs1057519991
TP53
G 0.710 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121912656
rs121912656
TP53
T 0.710 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121912656
rs121912656
TP53
A 0.710 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121912656
rs121912656
TP53
G 0.710 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016